UNCY - Cash Flow Statement - Unicycive Therapeutics, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018
OPERATING CASH FLOW
Net Income	(36.7)	(30.5)	(18.1)	(10.0)	(2.3)	(2.2)	(1.1)
Depreciation & Amortization	0.4	0.3	0.2	13 K	0	0	0
Deferred Income Tax	0	0	0	0.1	0	0	0
Stock Based Compensation	2.4	1.8	1.0	1.0	0.2	24 K	0
Other Operating Activities	5.8	10.3	21 K	3.2	0.7	0.7	0.3
Change in Working Capital	(0.4)	93 K	1.2	(0.1)	(0.2)	0.3	6 K
Cash From Operations	(28.6)	(18.3)	(15.7)	(5.8)	(1.5)	(1.2)	(0.8)
INVESTING CASH FLOW
Capital Expenditures	72 K	12 K	2 K	29 K	0	0	0
Other Items	0	0	0	0	0	0	0
Cash From Investing Activities	72 K	12 K	2 K	29 K	0	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0	0
Total Debt Repaid	0	0	0	0	1.4	0	0
Dividends Paid	(1.1)	0	0	0	0	0	0
Other Financing Activities	45.5	27.5	(0.5)	22.4	(0.1)	1.2	0.8
Cash From Financing Activities	45.1	27.5	(0.5)	22.4	1.4	1.2	0.8
CHANGE IN CASH
Net Change In Cash	16.4	9.2	(16.1)	16.6	15 K	10 K	25 K
FREE CASH FLOW
Free Cash Flow	(28.6)	(18.3)	(15.7)	(5.8)	(1.5)	(1.2)	(0.8)

Free